Glucagon Side Effects: What Studies Report
Published reports on glucagon rarely isolate glucagon alone. Most available adverse-event data come from trials and reviews of GLP-1 receptor agonists and of multi-receptor agonists that combine glucagon receptor activity with GIP and GLP-1 activity. Across these papers, researchers most often reported gastrointestinal events, with narrower discussion of pancreatic, hepatobiliary, cardiovascular, renal and dermatologic observations. Structured, glucagon-only adverse-event frequency tables were not present in the verified literature summarised here, and that gap is stated plainly below.
This page summarises what published studies and reviews reported about adverse events relevant to glucagon and glucagon receptor agonism. It describes findings only; it does not interpret them for any individual, and it does not characterise any compound as safe or unsafe. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.
What "glucagon" refers to in this literature
The word glucagon appears in the published literature in several distinct ways. It names a pancreatic hormone; it names approved emergency products used in clinical medicine; and it names a receptor target that drug developers have combined with incretin receptors in newer molecules. The third usage dominates the recent research record. Researchers described LY3437943 as a triple glucagon, GIP and GLP-1 receptor agonist developed for glycemic control and weight loss, and the paper traced the molecule from discovery through clinical proof of concept (PMID 35985340). A 2025 review of triple agonism based therapies for obesity covered the same general class of agents that add glucagon receptor activity to incretin receptor activity (PMID 40741227).
Glucagon receptor agonism has also been examined in liver disease research. A 2024 review in the World Journal of Gastroenterology discussed GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists as therapeutic agents under study for metabolic dysfunction-associated steatohepatitis (PMID 39735270). Because glucagon receptor activity in these programmes is delivered inside multi-receptor molecules, published adverse-event tallies generally describe the whole molecule rather than the glucagon component in isolation.
Study types behind the findings on this page
Readers comparing these sources are comparing different designs, and the design shapes what an adverse-event figure can mean. The sources summarised here include a retrospective cohort analysis of health claims data in adults prescribed GLP-1 receptor agonists for weight loss (PMID 37796527), an updated meta-analysis pooling randomised trial evidence on semaglutide (PMID 39046272), narrative and clinical-practice reviews (PMID 34775881), and a single-patient case report describing acute pancreatitis attributed to tirzepatide (PMID 39834977). Case reports describe one person and cannot generate a rate; cohort analyses can estimate association but not prove causation; pooled randomised trials report event frequencies within enrolled, selected populations.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeGastrointestinal Events: What Studies Report
Gastrointestinal complaints dominate the adverse-event record for this drug family. A 2022 clinical-practice review in Postgraduate Medicine addressed the gastrointestinal side effects of GLP-1 receptor agonists in obesity and set out recommendations for managing nausea, vomiting, diarrhoea and constipation in practice, describing these events as the most commonly encountered tolerability problem in the class (PMID 34775881). A 2024 review in Obesity Pillars examined weight loss outcomes alongside tolerability, side effects and risks for GLP-1 receptor agonists used in obesity, grouping gastrointestinal complaints as the principal reason tolerability is discussed in the literature (PMID 39286601).
Quantified comparisons come from larger datasets. Researchers conducting a retrospective cohort study of health claims data in adults using GLP-1 receptor agonists for weight loss reported an increased risk of pancreatitis, bowel obstruction and gastroparesis relative to a comparator weight-loss medication (PMID 37796527). An updated meta-analysis of randomised controlled trials evaluating the safety profile of semaglutide pooled adverse-event reporting across trials, with gastrointestinal events among the outcomes assessed (PMID 39046272). A 2021 safety review of semaglutide likewise placed gastrointestinal adverse effects at the centre of the drug's tolerability profile (PMID 34305810).
How gastrointestinal reporting differs between molecules
None of the verified sources isolated the gastrointestinal contribution of glucagon receptor agonism from that of GLP-1 or GIP receptor agonism within a combination molecule. The triple-agonist report described the molecule's progression from discovery to clinical proof of concept rather than publishing a class-wide adverse-event registry (PMID 35985340), and the 2025 triple agonism review summarised the emerging evidence base for obesity rather than a consolidated frequency table for glucagon alone (PMID 40741227).
Pancreatic and Hepatobiliary Events: What Studies Report
Pancreatitis appears in this literature in two different forms. In the claims-based cohort analysis, researchers reported an elevated risk of pancreatitis among adults using GLP-1 receptor agonists for weight loss compared with the active comparator (PMID 37796527). Separately, a 2024 case report in Cureus described acute pancreatitis in a patient receiving tirzepatide, a dual GIP/GLP-1 receptor agonist (PMID 39834977); a single case report describes one occurrence and does not establish incidence.
Review-level treatment of pancreatic and gallbladder questions appears in the 2021 semaglutide safety review, which discussed signals raised around pancreatitis, gallbladder-related events, thyroid C-cell findings in rodent studies and diabetic retinopathy alongside the gastrointestinal profile (PMID 34305810). Hepatic endpoints are the explicit subject of the steatohepatitis review, which assessed GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists as candidate agents in metabolic dysfunction-associated steatohepatitis (PMID 39735270).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appMetabolic and Glycaemic Observations: What Studies Report
Because glucagon receptor agonism is built into molecules designed for metabolic endpoints, metabolic outcomes and metabolic adverse events are reported together in the same papers. The triple agonist report described LY3437943 as developed for glycemic control and weight loss and followed it from discovery into clinical proof of concept (PMID 35985340). A 2025 review in Nature Reviews Drug Discovery surveyed GLP-1-based therapies for diabetes, obesity and beyond, including the expanding set of multi-receptor agents (PMID 40281304). The 2024 Obesity Pillars review grouped tolerability, side effects and risks alongside weight-loss outcomes rather than separating them (PMID 39286601).
Cardiovascular and Renal Findings: What Studies Report
A 2026 Lancet review examined glucagon-like receptor agonists and next-generation incretin-based medications and summarised metabolic, cardiovascular and renal outcomes reported for the class (PMID 41547366). The 2025 Nature Reviews Drug Discovery survey covered the same therapeutic territory from a drug-development perspective, including agents that extend beyond diabetes and obesity indications (PMID 40281304). Neither source published a glucagon-specific cardiovascular or renal adverse-event table, and this page does not supply one.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeDermatologic and Hair-Related Observations: What Studies Report
A 2025 paper in Skin Appendage Disorders reviewed dermatologic implications of glucagon-like peptide-1 receptor agonist medications, collecting skin and hair-related observations that have been described in users of these drugs (PMID 41058954). The review addressed GLP-1 receptor agonists rather than glucagon receptor agonism specifically, so the findings cannot be transferred to glucagon alone.
Where the Data Stop
Stated plainly: the verified literature summarised on this page does not contain a structured, frequency-ranked adverse-event dataset for glucagon used on its own. What exists instead is (a) adverse-event reporting for GLP-1 receptor agonists, where researchers reported gastrointestinal events most often and also examined pancreatitis, bowel obstruction and gastroparesis (PMID 37796527), and (b) development and review papers on multi-receptor molecules in which glucagon receptor activity is one of two or three pharmacological components (PMID 35985340, PMID 40741227). Doses, titration schedules and event rates specific to glucagon are therefore omitted here rather than estimated.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeSummary Table: What Each Source Reported
| System or topic | Study type and population | What was reported |
|---|---|---|
| Gastrointestinal | Retrospective cohort, claims data, adults using GLP-1 receptor agonists for weight loss | Increased risk of pancreatitis, bowel obstruction and gastroparesis versus comparator (PMID 37796527) |
| Gastrointestinal | Clinical-practice review, obesity | Nausea, vomiting, diarrhoea and constipation addressed as the class's main tolerability issue, with management recommendations (PMID 34775881) |
| Pooled safety | Updated meta-analysis of randomised trials, semaglutide | Adverse-event profile pooled across trials (PMID 39046272) |
| Pancreatic, gallbladder, thyroid, retinal | Safety review, semaglutide | Discussion of reported signals and residual questions (PMID 34305810) |
| Pancreatic | Case report, single patient, tirzepatide | Acute pancreatitis described in one case (PMID 39834977) |
| Hepatic | Review, metabolic dysfunction-associated steatohepatitis | GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists assessed as therapeutic agents (PMID 39735270) |
| Cardiovascular and renal | Review, incretin-based medications | Metabolic, cardiovascular and renal outcomes summarised for the class (PMID 41547366) |
| Dermatologic | Review, GLP-1 receptor agonist users | Skin and hair-related implications collected (PMID 41058954) |
| Multi-receptor agonism | Discovery-to-phase-1 report and obesity review | Glucagon receptor activity combined with GIP and GLP-1 activity for glycemic control and weight loss (PMID 35985340, PMID 40741227) |
Reading These Findings Carefully
- Molecule, not mechanism. Adverse events were reported for whole drugs; the verified sources did not attribute events to the glucagon receptor component alone (PMID 35985340).
- Design limits inference. The claims-based cohort reported associations in routine care rather than randomised comparisons (PMID 37796527).
- Population matters. Trial and review populations in these papers were adults studied for diabetes, obesity or liver disease endpoints (PMID 39286601, PMID 39735270).
- Absence of data is not absence of risk. Where the verified set carried no structured frequency data for glucagon alone, that absence is stated rather than filled in (PMID 40281304).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRelated Reading
A broader background overview of this molecule, including what it is and how it has been studied, sits on the PeptideU glucagon overview.
References
- Safety of Semaglutide (Frontiers in Endocrinology, 2021)
- GLP-1-based therapies for diabetes, obesity and beyond (Nature Reviews Drug Discovery, 2025)
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Cell Metabolism, 2022)
- Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (Lancet, 2026)
- Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks (Obesity Pillars, 2024)
- Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice (Postgraduate Medicine, 2022)
- Triple Agonism Based Therapies for Obesity (Current Cardiovascular Risk Reports, 2025)
- GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis (World Journal of Gastroenterology, 2024)
- Acute Pancreatitis Caused by Tirzepatide (Cureus, 2024)
- Evaluating the safety profile of semaglutide: an updated meta-analysis (Current Medical Research and Opinion, 2024)
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (JAMA, 2023)
- Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications (Skin Appendage Disorders, 2025)
Frequently asked questions
Do published studies report adverse events for glucagon on its own?▾
Not in the literature summarised here. The available reports describe whole molecules, such as the triple glucagon, GIP and GLP-1 receptor agonist followed from discovery to clinical proof of concept (PMID 35985340), or reviews of triple agonism based therapies for obesity (PMID 40741227). Structured, glucagon-only adverse-event frequency data were absent from this verified set, and that gap is stated rather than estimated.
Which adverse events were reported most often in this drug family?▾
Gastrointestinal complaints. A clinical-practice review addressed nausea, vomiting, diarrhoea and constipation as the principal tolerability issue with GLP-1 receptor agonists in obesity and offered management recommendations (PMID 34775881). A 2024 review of GLP-1 receptor agonists for obesity similarly grouped tolerability, side effects and risks alongside weight-loss outcomes (PMID 39286601).
What did the JAMA cohort analysis report?▾
Researchers used health claims data from adults prescribed GLP-1 receptor agonists for weight loss and reported an increased risk of pancreatitis, bowel obstruction and gastroparesis compared with an active weight-loss comparator (PMID 37796527). The study was observational, so it described an association within routine care rather than establishing causation for any individual event.
Has pancreatitis been described in case reports?▾
Yes. A 2024 case report in Cureus described acute pancreatitis in a patient receiving tirzepatide, a dual GIP/GLP-1 receptor agonist (PMID 39834977). A single case report documents one occurrence and cannot generate an incidence rate. Pancreatitis was also discussed at review level among the signals examined for semaglutide (PMID 34305810).
Were skin or hair effects reported?▾
A 2025 review in Skin Appendage Disorders collected dermatologic implications described with glucagon-like peptide-1 receptor agonist medications, covering skin and hair-related observations (PMID 41058954). The review concerned GLP-1 receptor agonists rather than glucagon receptor agonism specifically, so its findings were not attributed to glucagon alone.
What did reviews say about cardiovascular and renal outcomes?▾
A 2026 Lancet review of glucagon-like receptor agonists and next-generation incretin-based medications summarised metabolic, cardiovascular and renal outcomes reported for the class (PMID 41547366). A 2025 Nature Reviews Drug Discovery survey covered GLP-1-based therapies for diabetes, obesity and beyond from a development perspective (PMID 40281304). Neither published a glucagon-specific adverse-event table.
Why do these pages discuss GLP-1 drugs when the topic is glucagon?▾
Because glucagon receptor activity is usually studied inside multi-receptor molecules. Reviews examined GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists together as candidate agents for metabolic dysfunction-associated steatohepatitis (PMID 39735270), and pooled safety analyses of semaglutide form much of the quantified adverse-event record for the wider class (PMID 39046272).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.